ABCL
AbCellera Biologics Inc.
There isn't enough reported data to score ABCL yet.
NVO
Novo Nordisk A/S
NVO's fundamentals are mixed: it turned 15% of its revenue into free cash flow, but its operating margin fell 3 points to 43%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
ABCL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
ABCL's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ABCL PE Valuation
ABCL has no meaningful PE right now: it lost money over the past year.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
ABCL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ABCL's losses to grow, with revenue growing. However, they disagree widely on these estimates.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
ABCL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.48 | +$0.09 |
| Q2 2026 | -$0.54 | +$0.01 |
| Q1 2026 | -$0.48 | +$0.08 |
| Q4 2025 | -$0.49 | +$0.06 |
| Q3 2025 | -$0.57 | +$0.03 |
| Q2 2025 | -$0.55 | -$0.02 |
| Q1 2025 | -$0.56 | -$0.05 |
| Q4 2024 | -$0.55 | -$0.04 |
ABCL is still losing money, but less than at its worst: $0.48 per share over the past year, against $0.60 at its worst in late 2024.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over ABCL on earnings quality, reporting a profit while its opponent remains loss making.
ABCL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.6M | +19% |
| Q2 2026 | $4.1M | -76% |
| Q1 2026 | $8.3M | +96% |
| Q4 2025 | $44.9M | +788% |
| Q3 2025 | $9M | +38% |
| Q2 2025 | $17.1M | +133% |
| Q1 2025 | $4.2M | -57% |
| Q4 2024 | $5.1M | -45% |
ABCL's revenue is recovering but still below its 2022 peak: $11M last quarter, up 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -501% | +351 points |
| Q2 2026 | -1550% | -1260 points |
| Q1 2026 | -692% | +788 points |
| Q4 2025 | -64% | +1377 points |
| Q3 2025 | -852% | +588 points |
| Q2 2025 | -290% | +986 points |
| Q1 2025 | -1480% | -928 points |
| Q4 2024 | -1441% | -721 points |
ABCL's operating margin was −501% last quarter, up 351 points from the same quarter a year ago.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over ABCL on profitability, with a higher operating margin.
ABCL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $25.3M | +$86.8M |
| Q2 2026 | $23.8M | +$69.6M |
| Q1 2026 | -$37.4M | -$15.2M |
| Q4 2025 | -$44.6M | -$21M |
| Q3 2025 | -$61.5M | -$14.1M |
| Q2 2025 | -$45.8M | +$4.3M |
| Q1 2025 | -$22.2M | +$43.7M |
| Q4 2024 | -$23.6M | +$10.4M |
ABCL has burned cash in most quarters: −$33M over the past year, against −$153M the year before.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over ABCL on cash generation, producing positive trailing cash flow while its opponent burns cash.
ABCL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.1% | +12.5M shares |
| 1 year | +6.4% | +19.2M shares |
| 3 years | +9.9% | +28.6M shares |
| 5 years | +14% | +39.1M shares |
| Available history | +34% | +80.3M shares |
ABCL has 318M diluted shares, up 6.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over ABCL on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
ABCL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -1.6x | Net Cash |
| Q3 2022 | -1.1x | Net Cash |
| Q2 2022 | -2.8x | Net Cash |
| Q1 2022 | -1.9x | Net Cash |
| Q4 2021 | -2.2x | Net Cash |
| Q4 2020 | -3.5x | Net Cash |
| Q3 2020 | -12.0x | Net Cash |
| Q2 2020 | -14.9x | Net Cash |
ABCL has more cash than debt.
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
ABCL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.4 | Neutral |
| Stochastic | 62.7 | Neutral |
ABCL's weekly RSI is 61 (neutral) and its Stochastic is 63 (neutral).
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
ABCL PE vs Healthcare Sector
| Metric | ABCL | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ABCL has no meaningful PE right now: it lost money over the past year.
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
ABCL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.3 | 5.5% below |
| 20 week MA | $10.3 | 12% above |
| 50 week MA | $6.63 | 75% above |
| 100 week MA | $5.07 | 129% above |
| 200 week MA | $5.06 | 130% above |
ABCL has the edge over NVO on trend strength, trading above more of its moving averages.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has bounced recently, but its long-term trend is still down: it's above its 8-week average, but 50% below its 200-week average.
ABCL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58.9 | $42.4 | -28% |
| 2021 | $42.4 | $14.9 | -65% |
| 2022 | $14.9 | $10.3 | -31% |
| 2023 | $10.3 | $5.71 | -45% |
| 2024 | $5.71 | $2.99 | -48% |
| 2025 | $2.99 | $3.58 | +20% |
| 2026 YTD | $3.58 | $11.6 | +225% |
ABCL has the edge over NVO on returns for 2026, with the stronger performance.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has finished higher in four of the last six years, two of them by more than 50%. It's down 22% so far in 2026.